Social Media Ideas for Jnj:ca

I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)

Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

J&J has more than 28 sources of blockbuster revenue.

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

The company is firing on all cylinders.

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17 th, 2026. Management will participate in a Fireside Chat at 12:...

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

Looking for a dividend stock you can sleep well owning? Here's why Johnson & Johnson could be the long-term healthcare anchor your portfolio needs.

Johnson & Johnson to pay $5.5 bln to settle talc-related cancer lawsuits

J&J Snack Foods Corp. (JJSF) Q3 2026 Earnings Call Transcript

Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Johnson & Johnson offers $5.5B talc lawsuit settlement

Johnson & Johnson proposes a $5.5B settlement to resolve 76,000 talc lawsuits alleging baby powder caused ovarian cancer. The post Johnson & Johnson offers $5.5B talc lawsu...

Johnson & Johnson offers $5.5B to settle baby powder cancer lawsuits

The New Jersey-based drugmaker has been fighting talc-related lawsuits for more than a decade and said the settlement was a last-ditch effort to put the matter to bed.

GSK: Still One Of My Top Healthcare Picks

Stryker Corporation: Hold For Quality, Wait For The Dip

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

These two high-quality dividend payers have had very different fortunes recently.

Majestic Gold declares CAD 0.0055 special cash dividend

Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?

SA Asks: What's the outlook for Big Pharma M&A?

Johnson & Johnson offers $5.5 billion to settle talc lawsuits

US pharmaceutical giant Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming that its talcum powder products caused ovarian cancer, the c...

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C